Science

Leveraging TSLP biology to address a root cause of respiratory diseases driven by chronic inflammation

Verekitug is a novel monoclonal antibody that binds to the TSLP receptor and inhibits pro-inflammatory signaling initiated by TSLP. It is the only known clinical-stage monoclonal antibody that potently targets and inhibits the TSLP receptor.

TSLP: an upstream mediator for key inflammatory pathways

TSLP (thymic stromal lymphopoietin) is a cytokine that is a key driver of the inflammatory response in major allergic and inflammatory diseases, such as asthma, where disruption of TSLP signaling has been clinically validated as an effective therapeutic strategy.

TSLP activation is one of the first events in the inflammatory cascade stimulated by allergens, viruses and other triggers, initiating the activation of downstream targets such as IL-4, IL-5, IL-13, IL-17 and IgE.

Because TSLP is a target upstream in the inflammatory cascade, blocking the TSLP receptor presents an opportunity for a single treatment to impact the drivers of multiple pathological inflammatory processes across a broad set of respiratory diseases, including asthma, CRSwNP and COPD.

TSLP binding to its receptor complex is crucial, as it is the first step in initiating its biological activity and sets in motion the pro-inflammatory signaling cascade. By binding to the TSLP receptor, verekitug prevents TSLP from doing so and disrupts this process.

Preclinical and clinical data to date demonstrate verekitug’s highly potent inhibition of the TSLP receptor. In clinical trials, verekitug has demonstrated rapid, substantial, and sustained TSLP receptor inhibition for up to 24 weeks after the last dose. We believe this unique mechanism of action may translate to differentiated efficacy and less frequent dosing as compared to currently approved biologic therapies.

Learn more about verekitug

TSLP plays a key role upstream in a signaling cascade that drives inflammation